AI Health & Biotechnology

OpenAI Debuts GPT-Rosalind AI for Life Sciences

New specialized model aims to speed up drug discovery and biological research with partners Amgen and Moderna.

By Kronos Digital News Desk··1 min read
A digital DNA double helix glows on a computer screen inside a modern biotechnology laboratory where a scientist is working.

A digital DNA double helix glows on a computer screen inside a modern biotechnology laboratory where a scientist is working.

Photo: Kronos Digital News

OpenAI has launched GPT-Rosalind, its first artificial intelligence model specialized for the life sciences [1]. The new system aims to accelerate drug discovery and complex biological research [1][3]. Named after DNA pioneer Rosalind Franklin, the model helps scientists generate hypotheses and manage intricate scientific workflows [1]. Pharmaceutical leaders Amgen and Moderna are currently piloting the technology to streamline their research processes [1]. GPT-Rosalind enters a competitive field, positioning OpenAI against established research tools like Google’s AlphaFold [2]. The model focuses on processing vast biological datasets to support specialized medical innovation [2][3].

Editorial notes

Transparency note

Drafted with LLM; human-edited

AI assisted
Yes
Human review
Yes
Last updated

Risk assessment

Under review

Reviewed for sourcing quality and editorial consistency.

Sources

Related stories

View all

Topics

Get the weekly briefing

A concise briefing with selected stories and analysis.

No spam. Unsubscribe anytime. By joining, you agree to our Privacy Policy.

About the author

Kronos Digital News Desk covers ai health & biotechnology and editorial analysis for Kronos Digital News.